Table 4 Baseline characteristics of patients included in the INPULSIS® pooled data set, by stratification subgroup (analysis 3)
Entire cohort (N = 1061) | GAP | FVC | DLCO | CPI | SGRQ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
I (n = 500) | II/III (n = 560) | > 80% (n = 485) | ≤ 80% (n = 576) | > 40% (n = 709) | ≤ 40% (n = 351) | ≤ 45 (n = 462) | > 45 (n = 598) | ≤ 40 (n = 555) | > 40 (n = 488) | ||
Women, n (%) | 220 (20.7) | 160 (32.0) | 59 (10.5) | 119 (24.5) | 101 (17.5) | 136 (19.2) | 83 (23.6) | 102 (22.1) | 117 (19.6) | 99 (17.8) | 112 (23.0) |
Age, years | 66.8 (8.0) | 63.0 (8.1) | 70.1 (6.3) | 67.8 (7.7) | 65.9 (8.2) | 66.4 (8.0) | 67.4 (8.1) | 66.1 (8.0) | 67.2 (8.1) | 66.1 (7.9) | 67.4 (8.2) |
Time since IPF diagnosis, years | 1.6 (1.3) | 1.6 (1.3) | 1.7 (1.3) | 1.6 (1.3) | 1.7 (1.3) | 1.6 (1.3) | 1.7 (1.4) | 1.6 (1.3) | 1.6 (1.3) | 1.5 (1.3) | 1.7 (1.3) |
Ethnicity, n (%) | |||||||||||
White | 608 (57.3) | 283 (56.6) | 324 (57.9) | 263 (54.2) | 345 (59.9) | 426 (60.1) | 181 (51.6) | 273 (59.1) | 334 (55.9) | 297 (53.5) | 301 (61.7) |
Black | 2 (0.2) | 0 (0) | 2 (0.4) | 0 (0) | 2 (0.3) | 2 (0.3) | 0 (0) | 0 (0) | 2 (0.3) | 1 (0.2) | 1 (0.2) |
Asian | 322 (30.3) | 154 (30.8) | 168 (30.0) | 154 (31.8) | 168 (29.2) | 198 (27.9) | 124 (35.3) | 134 (29.0) | 188 (31.4) | 188 (33.9) | 133 (27.3) |
Missing | 129 (12.2) | 63 (12.6) | 66 (11.8) | 68 (14.0) | 61 (10.6) | 83 (11.7) | 46 (13.1) | 55 (11.9) | 74 (12.4) | 69 (12.4) | 53 (10.9) |
BMI, kg/m2 | 27.9 (4.6) | 28.2 (4.5) | 27.6 (4.6) | 27.6 (4.1) | 28.1 (5.0) | 28.2 (4.5) | 27.3 (4.6) | 28.1 (4.2) | 27.8 (4.8) | 27.3 (3.9) | 28.6 (5.1) |
Smoking history, n (%) | |||||||||||
Non-smoker | 296 (27.9) | 161 (32.2) | 134 (23.9) | 127 (26.2) | 169 (29.3) | 192 (27.1) | 103 (29.3) | 130 (28.1) | 165 (27.6) | 145 (26.1) | 146 (29.9) |
Ex-smoker | 718 (67.7) | 308 (61.6) | 410 (73.2) | 325 (67.0) | 393 (68.2) | 480 (67.7) | 238 (67.8) | 302 (65.4) | 416 (69.6) | 383 (69.0) | 322 (66.0) |
Current smoker | 47 (4.4) | 31 (6.2) | 16 (2.9) | 33 (6.8) | 14 (2.4) | 37 (5.2) | 10 (2.8) | 30 (6.5) | 17 (2.8) | 27 (4.9) | 20 (4.1) |
Comorbidities, n (%) | |||||||||||
PH | 30 (2.8) | 7 (1.4) | 23 (4.1) | 15 (3.1) | 15 (2.6) | 17 (2.4) | 13 (3.7) | 10 (2.2) | 20 (3.3) | 10 (1.8) | 20 (4.1) |
COPD | 27 (2.5) | 9 (1.8) | 18 (3.2) | 11 (2.3) | 16 (2.8) | 17 (2.4) | 10 (2.8) | 10 (2.2) | 17 (2.8) | 9 (1.6) | 18 (3.7) |
Lung cancera | 4 (0.4) | 2 (0.4) | 2 (0.4) | 3 (0.6) | 1 (0.2) | 3 (0.3) | 1 (0.3) | 2 (0.4) | 2 (0.4) | 1 (0.2) | 3 (0.6) |
GERD | 248 (23.4) | 113 (22.6) | 135 (24.1) | 115 (23.7) | 133 (23.1) | 178 (25.1) | 70 (19.9) | 118 (25.5) | 130 (21.7) | 108 (19.5) | 133 (27.3) |
CAD | 88 (8.3) | 26 (5.2) | 62 (11.1) | 36 (7.4) | 52 (9.0) | 54 (7.6) | 34 (9.7) | 29 (6.3) | 59 (9.9) | 44 (7.9) | 44 (9.0) |
FVC, % predicted | 79.6 (17.8) | 86.4 (17.9) | 73.5 (15.3) | 95.2 (12.9) | 66.4 (8.0) | 83.3 (18.0) | 72.1 (14.9) | 90.4 (17.2) | 71.2 (13.2) | 83.1 (18.1) | 75.4 (16.7) |
FEV1/FVC ratio | 81.7 (5.9) | 81.3 (5.8) | 82.0 (6.0) | 79.8 (5.8) | 83.2 (5.5) | 81.0 (5.9) | 83.1 (5.7) | 79.5 (5.8) | 83.3 (5.4) | 81.0 (5.7) | 82.4 (6.1) |
DLCO, % predicted | 47.2 (13.5)† | 53.8 (13.9) | 41.4 (9.9) | 51.3 (12.9) | 43.8 (13.0) | 53.8 (11.4) | 33.9 (4.6) | 58.2 (11.7) | 38.8 (7.2) | 49.5 (12.4) | 44.8 (14.2) |